Ardelyx, Inc. (ARDX)
Nasdaq · Healthcare · Biotechnology
$3.39+1.50%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $875M
- Forward P/E
- 11.7
- 52-week range
- $3.28 – $8.40
- 52-week change
- −35.40%
- EPS (trailing)
- −$0.23
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $407M (+22.09%)
- Net income
- −$62.0M
- Operating margin
- −10.1%
- Diluted EPS
- −$0.26
- Free cash flow
- −$44.0M
From the company’s annual report on SEC EDGAR.
About Ardelyx, Inc.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Headquarters: Waltham, United States · 489 employees · ardelyx.com